Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

This study has been terminated.
(lack of recruitment)
Sponsor:
Information provided by (Responsible Party):
Philogen S.p.A.
ClinicalTrials.gov Identifier:
NCT01198522
First received: September 8, 2010
Last updated: November 19, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2014
  Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)